SUMMARY OF PRODUCT CHARACTERISTICS 1. NAME OF
... reassessed. Asthmatic patients whose conditions deteriorates despite salbutamol therapy, or where a previously effective dose fails to give relief for at least three hours, should seek medical advice in order that any necessary additional steps may be taken. The dosage or frequency of administration ...
... reassessed. Asthmatic patients whose conditions deteriorates despite salbutamol therapy, or where a previously effective dose fails to give relief for at least three hours, should seek medical advice in order that any necessary additional steps may be taken. The dosage or frequency of administration ...
imitrex nasal spray
... Myocardial Ischemia, Myocardial Infarction, and Prinzmetal’s Angina The use of IMITREX Nasal Spray is contraindicated in patients with ischemic or vasospastic CAD. There have been rare reports of serious cardiac adverse reactions, including acute myocardial infarction, occurring within a few hours f ...
... Myocardial Ischemia, Myocardial Infarction, and Prinzmetal’s Angina The use of IMITREX Nasal Spray is contraindicated in patients with ischemic or vasospastic CAD. There have been rare reports of serious cardiac adverse reactions, including acute myocardial infarction, occurring within a few hours f ...
AusPAR: Regorafenib
... Bayer proposes registration of 40 mg, unscored, film-coated tablets. These are light-pink ovals (16 x 7 mm) marked “Bayer” and “40” on opposite sides. They are presented in an high density polyethylene (HDPE) bottle, with a child-resistant cap, of 28 tablets as a pack of 1 or 3 bottles (that is, 84 ...
... Bayer proposes registration of 40 mg, unscored, film-coated tablets. These are light-pink ovals (16 x 7 mm) marked “Bayer” and “40” on opposite sides. They are presented in an high density polyethylene (HDPE) bottle, with a child-resistant cap, of 28 tablets as a pack of 1 or 3 bottles (that is, 84 ...
Making sense of itraconazole pharmacokinetics
... Neutropenic antifungal prophylaxis depends on pharmacokinetics of itraconazole 631 – 358 ng/mL to 1292 – 357 ng/mL and from 8770 – 5050 ng·h/mL to 25 154 – 6460 ng·h/mL, respectively. Children appeared to be the only group of patients in whom the Cmin at 14 days did not usually exceed 500 ng/mL. Th ...
... Neutropenic antifungal prophylaxis depends on pharmacokinetics of itraconazole 631 – 358 ng/mL to 1292 – 357 ng/mL and from 8770 – 5050 ng·h/mL to 25 154 – 6460 ng·h/mL, respectively. Children appeared to be the only group of patients in whom the Cmin at 14 days did not usually exceed 500 ng/mL. Th ...
NOACS - West Suffolk Clinical Commissioning Group
... non-inferior to warfarin at reducing the risk of stroke and systemic embolism in people with AF Dabigatran standard dose (150mg twice daily) statistically significantly more effective in preventing stroke, particularly haemorrhagic stroke, in people with AF with a moderate/ high risk of stroke, co ...
... non-inferior to warfarin at reducing the risk of stroke and systemic embolism in people with AF Dabigatran standard dose (150mg twice daily) statistically significantly more effective in preventing stroke, particularly haemorrhagic stroke, in people with AF with a moderate/ high risk of stroke, co ...
AuspAR: Cabazitaxel - Therapeutic Goods Administration
... management approach designed to ensure therapeutic goods supplied in Australia meet acceptable standards of quality, safety and efficacy (performance), when ...
... management approach designed to ensure therapeutic goods supplied in Australia meet acceptable standards of quality, safety and efficacy (performance), when ...
dabigatran - UHN Research
... Low dose: 110 mg orally twice daily (recommended for patients >80 years or >75 years with risk factors for bleeding) Pharmacologic Profile And Laboratory Monitoring There is no specific antidote. Reversal of anticoagulant effect is theoretically possible with factor VIIa, but clinical data are l ...
... Low dose: 110 mg orally twice daily (recommended for patients >80 years or >75 years with risk factors for bleeding) Pharmacologic Profile And Laboratory Monitoring There is no specific antidote. Reversal of anticoagulant effect is theoretically possible with factor VIIa, but clinical data are l ...
Prior Elicitation in Bayesian Clinical Trial Design
... 1. Its first purpose is to treat the patients in the trial. 2. Its second purpose is to collect information that may be useful to evaluate existing treatments or develop new, better treatments to benefit future patients. Other, related purposes of clinical trials: 3. Generate data for research paper ...
... 1. Its first purpose is to treat the patients in the trial. 2. Its second purpose is to collect information that may be useful to evaluate existing treatments or develop new, better treatments to benefit future patients. Other, related purposes of clinical trials: 3. Generate data for research paper ...
Product Monograph
... transcutaneous oxygen saturation is in excess of 95%, FiO2 should be reduced until saturation is 90 to 95%. If the improvement in chest expansion seems excessive, peak ventilator inspiratory pressures should be immediately reduced. Failure to reduce inspiratory ventilatory pressures rapidly can resu ...
... transcutaneous oxygen saturation is in excess of 95%, FiO2 should be reduced until saturation is 90 to 95%. If the improvement in chest expansion seems excessive, peak ventilator inspiratory pressures should be immediately reduced. Failure to reduce inspiratory ventilatory pressures rapidly can resu ...
IQUIX - MedConnections
... No teratogenic effect was observed when rabbits were dosed orally as high as 50 mg/kg/day, which corresponds to approximately 60 times the highest recommended maximum human ophthalmic dose, or when dosed intravenously as high as 25 mg/kg/day, corresponding to approximately 30 times the highest recom ...
... No teratogenic effect was observed when rabbits were dosed orally as high as 50 mg/kg/day, which corresponds to approximately 60 times the highest recommended maximum human ophthalmic dose, or when dosed intravenously as high as 25 mg/kg/day, corresponding to approximately 30 times the highest recom ...
Product Monograph - AstraZeneca Canada
... childbearing potential should be advised not to become pregnant while receiving FASLODEX. If a patient becomes pregnant while receiving FASLODEX she should be apprised of the potential hazard to the fetus, or the potential risk for loss of pregnancy. Nursing Women: FASLODEX is contraindicated in lac ...
... childbearing potential should be advised not to become pregnant while receiving FASLODEX. If a patient becomes pregnant while receiving FASLODEX she should be apprised of the potential hazard to the fetus, or the potential risk for loss of pregnancy. Nursing Women: FASLODEX is contraindicated in lac ...
a guide to use of common palliative care drugs in renal impairment
... Opioids differ in their potential to cause toxicity when renal function is impaired. However, the evidence base from clinical studies is limited, and stratification of risk is based on the presence of active metabolites, risk of accumulation, and expert opinion. The pharmacokinetics and pharmacodyna ...
... Opioids differ in their potential to cause toxicity when renal function is impaired. However, the evidence base from clinical studies is limited, and stratification of risk is based on the presence of active metabolites, risk of accumulation, and expert opinion. The pharmacokinetics and pharmacodyna ...
The Role of Subcutaneous Ketorolac for Pain Management
... observations of 36 inpatients with advanced malignant disease–associated pain treated with ketorolac CSI. All patients were receiving oral opioids. Prior to initiation of the ketorolac CSI at a rate of 60 mg over 24 hours, a verbal 4-point rating of the patient’s pain was obtained. Oral misoprostol ...
... observations of 36 inpatients with advanced malignant disease–associated pain treated with ketorolac CSI. All patients were receiving oral opioids. Prior to initiation of the ketorolac CSI at a rate of 60 mg over 24 hours, a verbal 4-point rating of the patient’s pain was obtained. Oral misoprostol ...
Herbal Supplement - American Dental Hygienists Association
... Dental professionals routinely treat patients taking prescription, nonprescription, and herbal medications that are known or have the potential to alter bleeding. Prescription anticoagulant and antiplatelet medications, as well as over-the-counter drugs such as aspirin, are typically taken to reduce ...
... Dental professionals routinely treat patients taking prescription, nonprescription, and herbal medications that are known or have the potential to alter bleeding. Prescription anticoagulant and antiplatelet medications, as well as over-the-counter drugs such as aspirin, are typically taken to reduce ...
Top 300 Drug List
... Pregnancy category D (Cat C during first trimester). Drugs that act on the ReninAngiotensin system may result in injury and death to the developing fetus. D/C as soon as possible once pregnancy is detected or in a female who desires conception. May cause a dry cough, first-dose hypotension (especial ...
... Pregnancy category D (Cat C during first trimester). Drugs that act on the ReninAngiotensin system may result in injury and death to the developing fetus. D/C as soon as possible once pregnancy is detected or in a female who desires conception. May cause a dry cough, first-dose hypotension (especial ...
Rx only for women younger than age 17
... established in women of reproductive age. Safety and efficacy are expected to be the same for postpubertal adolescents less than 17 years and for users 17 years and older. Use of Next Choice One DoseTM emergency contraception before menarche is not indicated. 8.5 Geriatric Use This product is not in ...
... established in women of reproductive age. Safety and efficacy are expected to be the same for postpubertal adolescents less than 17 years and for users 17 years and older. Use of Next Choice One DoseTM emergency contraception before menarche is not indicated. 8.5 Geriatric Use This product is not in ...
Medical Management of Asymptomatic Primary Hyperparathyroidism
... PHPT, and advances in the surgical and medical management of PHPT (2– 8). Patients who do not meet surgical guidelines or are unable or unwilling to proceed with parathyroidectomy can be safely monitored. Medical management of these individuals is addressed in this section. Recently, data from three ...
... PHPT, and advances in the surgical and medical management of PHPT (2– 8). Patients who do not meet surgical guidelines or are unable or unwilling to proceed with parathyroidectomy can be safely monitored. Medical management of these individuals is addressed in this section. Recently, data from three ...
Running head: PERSONAL DRUGS PERSONAL DRUGS Personal
... Rare: anaphylaxis, acute pancreatitis, anorexia, Clostridium difficile associated diarrhea, hepatic failure, increased bleeding times, increased creatinine, Stevens-Johnson syndrome, thrombocytopenia Monitor: frequent monitoring of hepatic function (Lexicomp, 2014) Side Effects: Common: pruritus, ra ...
... Rare: anaphylaxis, acute pancreatitis, anorexia, Clostridium difficile associated diarrhea, hepatic failure, increased bleeding times, increased creatinine, Stevens-Johnson syndrome, thrombocytopenia Monitor: frequent monitoring of hepatic function (Lexicomp, 2014) Side Effects: Common: pruritus, ra ...
PID comments (clarifax in January 2006) - Bristol
... On-treatment value worsened from baseline to Grade 3 or Grade 4 for all parameters except albumin (any on treatment value <2.5 g/dL), confirmed creatinine increase ≥ 44.2 mmol/L and ALT >10 X ULN and >2 X baseline. Studies AI463022 and AI463027. . Mean duration of therapy was 69 weeks for BARACLUDE- ...
... On-treatment value worsened from baseline to Grade 3 or Grade 4 for all parameters except albumin (any on treatment value <2.5 g/dL), confirmed creatinine increase ≥ 44.2 mmol/L and ALT >10 X ULN and >2 X baseline. Studies AI463022 and AI463027. . Mean duration of therapy was 69 weeks for BARACLUDE- ...
The Nebraska Medical Center Guidelines for Management of
... levels can vary widely between patients due to common polymorphisms in the primary metabolic enzyme. Drugdrug interactions are frequent and need careful consideration when beginning, altering, or discontinuing treatment. Contraindicated in pregnancy. • Posaconazole does not have an indication for tr ...
... levels can vary widely between patients due to common polymorphisms in the primary metabolic enzyme. Drugdrug interactions are frequent and need careful consideration when beginning, altering, or discontinuing treatment. Contraindicated in pregnancy. • Posaconazole does not have an indication for tr ...
PRODUCT MONOGRAPH MOVIPREP® Macrogol 3350, Sodium
... shortness of breath, increasing fatigue, cardiac failure), plasma electrolytes should be measured and any abnormality treated appropriately (see WARNINGS AND PRECAUTIONS – General). ADVERSE REACTIONS Adverse Drug Reaction Overview The majority of adverse events across all studies was related to gast ...
... shortness of breath, increasing fatigue, cardiac failure), plasma electrolytes should be measured and any abnormality treated appropriately (see WARNINGS AND PRECAUTIONS – General). ADVERSE REACTIONS Adverse Drug Reaction Overview The majority of adverse events across all studies was related to gast ...
Get Reacquainted With Clocortolone Pivalate
... Cloderm Cream was uniquely designed to provide upper-mid-level potency with an excellent safety profile in order to present a favorable treatment option for a wide range of patients. Per the prescribing information, the use of clocortolone pivalate 0.1% cream has no age restrictions. As suggested ab ...
... Cloderm Cream was uniquely designed to provide upper-mid-level potency with an excellent safety profile in order to present a favorable treatment option for a wide range of patients. Per the prescribing information, the use of clocortolone pivalate 0.1% cream has no age restrictions. As suggested ab ...
IOPIDINE ® Solution
... tolerated medical therapy may not provide much additional benefit. Since IOPIDINE 0.5% Ophthalmic Solution is an aqueous suppressing drug, the addition of a third aqueous suppressant may not significantly reduce IOP. ...
... tolerated medical therapy may not provide much additional benefit. Since IOPIDINE 0.5% Ophthalmic Solution is an aqueous suppressing drug, the addition of a third aqueous suppressant may not significantly reduce IOP. ...
Full Prescribing Information
... observed. Up to two or three times this dose (4 to 6 mg) may be required in severe cases. Removing contaminated clothing, washing the skin, and commencing artificial respiration and supportive therapy are also indicated. ...
... observed. Up to two or three times this dose (4 to 6 mg) may be required in severe cases. Removing contaminated clothing, washing the skin, and commencing artificial respiration and supportive therapy are also indicated. ...
LEMON BALM Mary Bove, ND An Overview of its Versatility, Effectiveness, and Indications
... essential oil content of the plant and that the top third of the leafy plant has the highest amount of volatile oil. 3 ...
... essential oil content of the plant and that the top third of the leafy plant has the highest amount of volatile oil. 3 ...
Dydrogesterone
Dydrogesterone (INN, USAN, BAN), is also chemically known as 9β,10α-pregna-4,6-diene-3,20-dione. Dydrogesterone (6-dehydro-retroprogesterone) is a hormonally active, non-androgenic steroid that was developed in the 1950s.Dydrogesterone has selective progestational activity and does not inhibit ovulation. The greater rigidity of dydrogesterone also positively affects its selectivity, while natural progesterone is less selective, existing in different conformations that more easily bind to different receptors. As a consequence of its better bioavailability and the progestational activity of its main metabolites (20-, 21- and 16-hydroxy derivatives), the equivalent dose of dydrogesterone is 10–20 times lower than that of oral micronized progesterone.Dydrogesterone is used as an effective, orally active progestogen for gynaecological conditions related to a wide variety of progesterone deficiencies in pregnant women. The molecular structure and pharmacological effects are somewhat similar to endogenous progesterone, although in smaller amounts it is found to be orally active. Its freedom from hormonal effects like those related to corticoid, androgenic, estrogenic, anabolic, and other effects gives dydrogesterone an advantage over other synthesized progestogens.Dydrogesterone when used therapeutically is closely related to its physiological action on the neuro-endocrine control of ovarian function, as well as on the endometrium. This is an indication in all cases of endogeneous progesterone deficiency - relative or absolute. The molecule was licensed for use in several indications, including threatened or recurrent miscarriage, dysfunctional bleeding, infertility due to luteal insufficiency, dysmenorrhea, endometriosis, secondary amenorrhoea, irregular cycles, pre-menstrual syndrome and also as a hormone replacement therapy.Dydrogesterone has proven effective in the following conditions associated with progesterone deficiency: Infertility due to luteal insufficiency Threatened miscarriage Habitual or recurrent miscarriage. Menstrual disorders Premenstrual syndrome Endometriosis Dydrogesterone has also been registered as hormone replacement therapy (HRT) to counter-check the negative effects of unopposed estrogen on the endometrium in women with an intact uterus. Dydrogesterone is relatively safe and well tolerated, and does not exhibit the androgenic side effects that are common with some other progestins, like medroxyprogesterone acetate.